IRIS Accounts Production v26.1.10.61 07974307 Board of Directors Board of Directors 1.4.25 31.3.26 31.3.26 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh079743072025-03-31079743072026-03-31079743072025-04-012026-03-31079743072024-03-31079743072024-04-012025-03-31079743072025-03-3107974307ns15:EnglandWales2025-04-012026-03-3107974307ns14:PoundSterling2025-04-012026-03-3107974307ns10:Director12025-04-012026-03-3107974307ns10:Director22025-04-012026-03-3107974307ns10:PrivateLimitedCompanyLtd2025-04-012026-03-3107974307ns10:SmallEntities2025-04-012026-03-3107974307ns10:AuditExempt-NoAccountantsReport2025-04-012026-03-3107974307ns10:SmallCompaniesRegimeForDirectorsReport2025-04-012026-03-3107974307ns10:SmallCompaniesRegimeForAccounts2025-04-012026-03-3107974307ns10:FullAccounts2025-04-012026-03-310797430712025-04-012026-03-3107974307ns10:RegisteredOffice2025-04-012026-03-3107974307ns5:CurrentFinancialInstruments2026-03-3107974307ns5:CurrentFinancialInstruments2025-03-3107974307ns5:ShareCapital2026-03-3107974307ns5:ShareCapital2025-03-3107974307ns5:RetainedEarningsAccumulatedLosses2026-03-3107974307ns5:RetainedEarningsAccumulatedLosses2025-03-3107974307ns5:NetGoodwill2025-04-012026-03-3107974307ns5:IntangibleAssetsOtherThanGoodwill2025-04-012026-03-3107974307ns5:PlantMachinery2025-04-012026-03-3107974307ns5:FurnitureFittings2025-04-012026-03-3107974307ns5:ComputerEquipment2025-04-012026-03-3107974307ns5:NetGoodwill2025-03-3107974307ns5:NetGoodwill2026-03-3107974307ns5:NetGoodwill2025-03-3107974307ns5:PlantMachinery2025-03-3107974307ns5:FurnitureFittings2025-03-3107974307ns5:ComputerEquipment2025-03-3107974307ns5:PlantMachinery2026-03-3107974307ns5:FurnitureFittings2026-03-3107974307ns5:ComputerEquipment2026-03-3107974307ns5:PlantMachinery2025-03-3107974307ns5:FurnitureFittings2025-03-3107974307ns5:ComputerEquipment2025-03-3107974307ns5:WithinOneYearns5:CurrentFinancialInstruments2026-03-3107974307ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-31
REGISTERED NUMBER: 07974307 (England and Wales)














Financial Statements for the Year Ended 31 March 2026

for

Npsych Clinical Neurosciences Ltd

Npsych Clinical Neurosciences Ltd (Registered number: 07974307)






Contents of the Financial Statements
for the Year Ended 31 March 2026




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 3


Npsych Clinical Neurosciences Ltd

Company Information
for the Year Ended 31 March 2026







DIRECTORS: Dr N H Walton
Dr R J McCarter





REGISTERED OFFICE: The Retreat
406 Roding Lane South
Woodford Green
Essex
IG8 8EY





REGISTERED NUMBER: 07974307 (England and Wales)





ACCOUNTANTS: Nordens
The Retreat
406 Roding Lane South
Woodford Green
Essex
IG8 8EY

Npsych Clinical Neurosciences Ltd (Registered number: 07974307)

Statement of Financial Position
31 March 2026

31.3.26 31.3.25
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Property, plant and equipment 5 13,099 17,161
13,099 17,161

CURRENT ASSETS
Debtors 6 204,167 105,150
Cash at bank and in hand 632,969 573,218
837,136 678,368
CREDITORS
Amounts falling due within one year 7 127,541 85,098
NET CURRENT ASSETS 709,595 593,270
TOTAL ASSETS LESS CURRENT
LIABILITIES

722,694

610,431

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 722,594 610,331
SHAREHOLDERS' FUNDS 722,694 610,431

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 16 June 2026 and were signed on its behalf by:




Dr N H Walton - Director



Dr R J McCarter - Director


Npsych Clinical Neurosciences Ltd (Registered number: 07974307)

Notes to the Financial Statements
for the Year Ended 31 March 2026

1. STATUTORY INFORMATION

Npsych Clinical Neurosciences Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2012, is being amortised evenly over its estimated useful life of ten years.

The directors have reviewed the value of goodwill and its remaining life and believe that the amounts shown in the financial statements for goodwill and goodwill amortisation are fairly stated.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 15% on reducing balance
Fixtures and fittings - 15% on reducing balance
Computer equipment - 25% on reducing balance

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2025 - 2 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 April 2025
and 31 March 2026 800,000
AMORTISATION
At 1 April 2025
and 31 March 2026 800,000
NET BOOK VALUE
At 31 March 2026 -
At 31 March 2025 -

Npsych Clinical Neurosciences Ltd (Registered number: 07974307)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026

5. PROPERTY, PLANT AND EQUIPMENT
Fixtures
Plant and and Computer
machinery fittings equipment Totals
£    £    £    £   
COST
At 1 April 2025 15,743 10,312 52,277 78,332
Additions - - 657 657
Disposals - - (1,521 ) (1,521 )
At 31 March 2026 15,743 10,312 51,413 77,468
DEPRECIATION
At 1 April 2025 14,067 9,813 37,291 61,171
Charge for year 252 75 3,750 4,077
Eliminated on disposal - - (879 ) (879 )
At 31 March 2026 14,319 9,888 40,162 64,369
NET BOOK VALUE
At 31 March 2026 1,424 424 11,251 13,099
At 31 March 2025 1,676 499 14,986 17,161

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.26 31.3.25
£    £   
Trade debtors 194,551 100,075
Other debtors 9,616 5,075
204,167 105,150

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.26 31.3.25
£    £   
Trade creditors 643 2,464
Taxation and social security 124,575 79,721
Other creditors 2,323 2,913
127,541 85,098

8. RELATED PARTY DISCLOSURES

The Directors Dr N H Walton and Dr R J McCarter are considered to be the key management personnel.